HOME >> MEDICINE >> NEWS
Postmenopausal hormone therapy offers no protection against heart attacks

Although therapy with hormones was once thought to protect women's hearts after menopause, a UCSF-led study has found that, at least for women with heart disease, estrogen plus progestin therapy does not reduce the risk of heart attack or death.

The July 3, 2002 issue of the Journal of the American Medical Association (JAMA) contains two articles with the results of the Heart and Estrogen/Progestin Replacement Follow-up Study (HERS II).

HERS was a randomized, blinded trial to determine the effects of estrogen plus progestin (compared with placebo) in older postmenopausal women with heart disease. In 1998 HERS scientists reported that, surprisingly, risk of heart attack increased in the hormone therapy group during the first year of HERS. The risk seemed to decrease in the next several years, leading to the HERS II follow-up study to evaluate the effects of longer-duration hormone therapy.

The trend toward a reduced risk of heart attacks did not persist with additional follow-up. During almost 7 years, combining HERS and HERS II, there was no reduction in risk among women taking hormones.

"This follow-up study found no reduction in risk of heart attacks or death for women with heart disease during up to seven years of hormone therapy. Not only was there no cardiovascular benefit, there were adverse affects, including blood clots and gallbladder disease," said Deborah Grady, MD, MPH, UCSF professor of epidemiology and medicine and co-principal investigator on the studies. Grady is also director of the UCSF/Mount Zion Women's Health Clinical Research Center.

The hormone therapy caused a 2-fold increase in the risk of blood clots in the legs and lungs, with most of the increased risk in the early years of treatment, according to principal investigator Stephen Hulley, MD, MPH, professor and chair of the UCSF department of epidemiology and biostatistics. There was a nearly 50 percent increase in the risk of gallbladder disease r
'"/>

Contact: Maureen McInaney
mmcinaney@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
2-Jul-2002


Page: 1 2

Related medicine news :

1. Postmenopausal breast cancer survivors at increased risk for bone fractures
2. Postmenopausal women have lower grip strength than premenopausal women
3. Postmenopausal hormone therapy associated with increased risk for developing asthma
4. Postmenopausal hormone replacement therapy linked to increased risk for certain types of rarely occurring breast cancer
5. Postmenopausal Women Reap Heart Benefits From Foods Containing Vitamin E
6. Novel Therapy Significantly Reduces Spinal Fractures In Postmenopausal WomenWith Two Years Of Therapy
7. New Drug Prevents Breast Cancer In Postmenopausal Women, UCSF Researchers Report
8. Growth hormone treatment improves symptoms of metabolic disorder in postmenopausal women
9. Mood elevating hormone may trigger depression and heart problems
10. The history and controversy behind post-menopausal hormone therapy
11. Female sex hormones play a vital role in defense against sexually transmitted diseases

Post Your Comments:
(Date:3/27/2015)... 2015 Bleeding is one of ... coronary intervention (PCI), resulting in increased mortality, morbidity, ... paradox,” in which the highest-risk PCI patients with ... less often with bleeding avoidance strategies than lower-risk ... America Heart Institute asked the question whether prospectively ...
(Date:3/27/2015)... Dallas, TX (PRWEB) March 27, 2015 ... Landscape – Germany” is an essential source of ... and reimbursement landscape in Germany. Germany’s increasingly elderly ... drivers of its pharmaceutical market. In 2013, the ... expected to increase at Compound Annual Growth Rate ...
(Date:3/27/2015)... 2015 On March 19, 2015, ... Detroit Lions wide receiver Herman Moore, hosted “Fighting ... on substance abuse, treatment options and the recent ... were pastors, ministers and bishops from local churches ... guests. , “Our ‘Fighting Addiction Together’ luncheon was ...
(Date:3/27/2015)... CA (PRWEB) March 27, 2015 SMI ... today announced it has launched the SM1120 MEMS based ... market. The microsensor profile at only 220um x ... maneuverability to reach challenging locations. With industry leading ... hour, the SM1120 provides a broad operating pressure range ...
(Date:3/27/2015)... 27, 2015 Trail mix is the perfect, ... on weekend hikes and during the game! It’s portable, lightweight ... is proud to introduce a new line of specialty trail ... rich and flavorful selections packed with nutritious, 100% all natural ... and grains that add protein and fiber to your diet ...
Breaking Medicine News(10 mins):Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4Health News:LiveToBeSober.org Hosts Conference on Substance Abuse Treatment and Recovery at Ford Field 2Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Aurora Product, Inc. Introduces New Line of Specialty Trail Mixes 2
(Date:3/27/2015)... -- Levi & Korsinsky announces it has commenced an ... concerning possible violations of federal securities laws. The investigation ... with its study of the drug OHR-102. To obtain ... Joseph E. Levi, Esq. either via email ... 363-7500, toll-free: (877) 363-5972. Levi & Korsinsky ...
(Date:3/27/2015)... 2015 Dynatronics Corporation (NASDAQ: DYNT ) today ... to the Company,s Board of Directors effective March 23, 2015, ... 2014 of board member Joseph Barton .  ... Board of Directors represents an important step forward for the ... of Dynatronics.  "Rich is a proven leader and is well-known ...
(Date:3/27/2015)... -- Biopharmaceutical Industry Leads Manufacturing Sector in R&D ... top as the country,s manufacturing leader in innovation and ... According to the  analysis , the industry had the ... decade, accounting for 27 percent of average annual R&D ... Video on Medicare Part D - Medicare Part ...
Breaking Medicine Technology:Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Week in Review: The Latest from PhRMA 2
Cached News: